Changshan Biochemical Pharmaceutical

Hebei Changshan Biochemical Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and large-scale production of heparin-based anticoagulants and metabolic disease therapies. As a leading global supplier of heparin sodium API, the company maintains a vertically integrated supply chain and offers a diverse portfolio of low molecular weight heparin (LMWH) products, including enoxaparin, dalteparin, and nadroparin. Changshan is currently diversifying its pipeline with a strong focus on GLP-1 receptor agonists, most notably albenatide, which is in late-stage clinical trials for type 2 diabetes and obesity. The company is headquartered in Shijiazhuang and is listed on the Shenzhen Stock Exchange, serving both domestic Chinese and international markets.